Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Trial Profile

Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 12 Oct 2018 Results reporting ongoing safety evaluations from ocrelizumab clinical trials and open-label extension (OLE) periods plus VELOCE, CHORDS, CASTING and OBOE trials up to February 2018 and updated post-marketing data presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 23 Aug 2018 Planned End Date changed from 10 Dec 2020 to 9 Dec 2021.
    • 19 Jun 2018 Results of updated safety analysis from this and other three studies presented at the 4th Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top